We are live on ! Find out more
PVMCV

Polaris Venture Management Co V Portfolio holdings

AUM $14.1M
1-Year Est. Return 121.41%
This Fund
S&P 500
This Quarter Est. Return
-20.21%
1 Year Est. Return
+121.41%
3 Year Est. Return
+281.18%
5 Year Est. Return
+1,023.01%
10 Year Est. Return
–
AUM
$93.2M
AUM Growth
-$11.5M
Cap. Flow
+$20.3M
Cap. Flow %
21.84%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
RNAC icon
Cartesian Therapeutics
RNAC
+$26.9M

Top Sells

Rank Stock Value
1
TRVN
Trevena, Inc.
TRVN
+$3M
2
OCUL icon
Ocular Therapeutix
OCUL
+$2.29M
3
TTOO
T2 Biosystems, Inc
TTOO
+$1.31M

Sector Composition

Rank Sector Weight
1 Healthcare 83.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAC icon
1
Cartesian Therapeutics
RNAC
$227M
$26.9M 28.9%
+64,138
New +$26.9M
TTOO
2
DELISTED
T2 Biosystems, Inc
TTOO
$14.8M 15.89%
375
-29
-7% -$1.31M
TRVN
3
DELISTED
Trevena, Inc.
TRVN
$14.3M 15.35%
3,633
-638
-15% -$3M
GNCA
4
DELISTED
Genocea Biosciences, Inc.
GNCA
$8.07M 8.66%
246,076
– –
PULM icon
5
Pulmatrix
PULM
$6.21M
$7.07M 7.59%
18,040
– –
DARE icon
6
Dare Bioscience
DARE
$18.6M
$6.97M 7.48%
27,396
– –
ATYR
7
aTyr Pharma
ATYR
$47.1M
$5.08M 5.46%
130,571
– –
OCUL icon
8
Ocular Therapeutix
OCUL
$1.85B
$4.94M 5.31%
998,713
-231,296
-19% -$2.29M
FATE icon
9
Fate Therapeutics
FATE
$293M
$4.2M 4.51%
2,473,186
– –
BIND
10
DELISTED
BIND THERAPEUTICS INC
BIND
$789K 0.85%
2,018,253
– –

Similar funds

IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
AG
Ashmore Group London, United Kingdom $16.3M AUM 57.83% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
CCM
Copernicus Capital Management San Francisco, California $8.26M AUM 37.91% 1-Year Est. Return
EIP
Edgbaston Investment Partners $20.3M AUM 35.98% 1-Year Est. Return
AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
OEP
Ocean Endowment Partners Chicago, Illinois $20.6M AUM 27.63% 1-Year Est. Return

Polaris Venture Management Co V's Q2 2016 Portfolio in Review

As of Q2 2016, Polaris Venture Management Co V held 10 positions worth $93.2M, down 11% from $105M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Polaris Venture Management Co V deployed $20.3M of net new capital in Q2 2016, opening 1 new position. Its largest new stake was Cartesian Therapeutics: 64,138 shares worth $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 77% a quarter earlier.

On the sell side, the largest reduction was Trevena, Inc., an estimated $3M trimmed.

  • Polaris Venture Management Co V's largest Q2 2016 buy was Cartesian Therapeutics: 64,138 shares worth $26.9M.
  • Polaris Venture Management Co V's biggest Q2 2016 reduction was Trevena, Inc., cutting an estimated $3M.
  • Polaris Venture Management Co V's ten largest holdings make up 100% of its $93.2M portfolio in Q2 2016.
  • Polaris Venture Management Co V opened 1 new position and closed 0 in Q2 2016.
  • Polaris Venture Management Co V's portfolio value fell 11% quarter-over-quarter to $93.2M.

Based on Polaris Venture Management Co V's 13F filing for Q2 2016, filed 28 Jul 2016.